The world is waiting for a blood test for stroke.
13.7 million people worldwide will have their first stroke this year and 5.5 million will die as a result.
Current trends suggest that the number of annual deaths will climb to 6.7 million annually without appropriate action.
Stroke Diagnosis
In the Real World
Diagnosing stroke is one of the most challenging situations for emergency medical professionals. A myriad of symptoms can coincide that are hallmarks of other serious complications making misdiagnosis common. With the potency and seriousness of thrombolytic drug administration, a doctor is faced with difficult clinical decisions treating a patient with stroke like symptoms.
$46b
Stroke related cost in the United States were $46 billion USD in 2014-2015.
Priority
The National Academy of Medicine has identified improving stroke diagnosis as a public health priority.
10%
Nearly 10% of strokes were misdiagnosed at first contact.
4 min
Every 4 minutes someone dies from stroke.
800,000 Strokes
In US every year
Every minute of brain hypoxia causes 2 million brain cells to die.
Stroke symptoms during emergencies
With no proper clinical stroke test beyond traditional identifications of visible symptoms and cues, emergency response, intensive care and front line physicians face challenging diagnostic struggles daily. These are often under intense time pressures.
Treatment to remove clots given less than 2 hours from onset results in significantly better outcomes for the patient.
Over 7.5 million Emergency Department patients have headache, vertigo &
dizziness that can mask ischaemic stroke when they arrive.
Evaluation Timing
A patient outlook during a stroke diagnoses is extremely time sensitive.
Conducting a bedside stroke test can provide timely and accurate information needed to provide appropriate medical care. is a solution for this dilemma.
Stroke Testing is Our Priority
Galaxy, a clinical contract research organization, is pleased to announce the launch of its company through a cornerstone product built on its license agreement with Proteome Sciences (London, UK) For the initial product launch, Galaxy is licensing intellectual property relating to blood biomarkers of stroke developed by Proteome Sciences in partnership with the University of Geneva and Geneva University Hospitals. Galaxy intends to develop and deliver a point of care prognostic device which will drive a doctor’s ability to determine when thrombolytic treatment can be administered for optimum clinical outcomes.
Our lateral flow stroke test.
We are developing a bedside stroke test that requires only a few drops of blood. This can be used by clinics, EMTs, nursing homes, ERs, or any other healthcare facility.